Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1
Recruiting in Palo Alto (17 mi)
Overseen byFrank AJL Scheer, PhD
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Brigham and Women's Hospital
No Placebo Group
Trial Summary
What is the purpose of this trial?
This project aims to test the impact of melatonin and MTNR1B variation on regulation glucose regulation in a highly controlled in-laboratory setting and ex vivo in pancreatic islets.
Eligibility Criteria
Inclusion Criteria
Age: 21-55 years of age
Body Mass Index: 20 and 35 kg/m2
Caucasian
See 3 more
Treatment Details
Interventions
- Melatonin (Melatonin Receptor Agonist)
- Placebo (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: placebo-melatoninExperimental Treatment2 Interventions
subjects will receive placebo first and melatonin second
Group II: melatonin-placeboExperimental Treatment2 Interventions
subjects will receive melatonin first and placebo second
Melatonin is already approved in European Union, European Union, United States for the following indications:
🇪🇺 Approved in European Union as Circadin for:
- Insomnia in adults aged 55 and over
- Sleep disorders in children with autism spectrum disorder
🇪🇺 Approved in European Union as Slenyto for:
- Insomnia in children and adolescents aged 2-18 with autism spectrum disorder
🇺🇸 Approved in United States as Melatonin for:
- Sleep disorders in children with autism spectrum disorder
- Insomnia in adults
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Brigham and Women's HospitalBoston, MA
Loading ...
Who Is Running the Clinical Trial?
Brigham and Women's HospitalLead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator